Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Stock Is Skyrocketing Today

By Keith Speights – Updated Jul 13, 2020 at 11:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about an analyst's bullish view about the biotech stock.

What happened

Shares of Vaxart (VXRT 0.94%) were skyrocketing 26.4% higher as of 11:22 a.m. EDT on Monday. The huge jump came after investment bank B. Riley FBR initiated coverage on the stock with a buy rating and a price target of $22. This price target represented a 176% premium over Vaxart's closing price on Friday.

So what

It's usually best to take analysts' price targets with a grain of salt. On the other hand, investors can benefit from trying to understand why analysts like or don't like a given stock. 

Rocket flying over a red line with an arrow

Image source: Getty Images.

In this case, B. Riley FBR appears to be very optimistic about the prospects for Vaxart's oral COVID-19 vaccine candidate. This experimental vaccine was recently selected by the U.S. government's Operation Warp Speed for funding and inclusion in a preclinical study. 

Keep in mind, though, that it's way too soon to know if Vaxart will be successful. In April, the company reported encouraging results for its oral COVID-19 vaccine candidate in preclinical testing. However, the vaccine candidate hasn't advanced to clinical testing yet.

Now what

Vaxart hopes to advance its oral COVID-19 vaccine candidate to a phase 1 study in the second half of 2020, potentially as early as this summer. Until that trial begins, probably the main catalyst for the biotech stock will be the results for preclinical testing of its universal oral flu vaccine candidate. This preclinical testing is being conducted in collaboration with Johnson & Johnson.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.